XVARY Composite Score
72
/ 100
Average
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
Alcon makes surgical gear, lenses, and eye-care products that help people see better.
How it gets paid
Last year Alcon made ~$10.3B in revenue. Contact lenses was the main engine at $3.0B, or 29% of sales.
Why it's growing
Revenue grew 5% last year. Core EPS missed by ~$0.04 vs the ~$0.82 consensus—pair the same non-GAAP definition the release uses.
What just happened
Q4 2025 net sales ~$2.7B; core diluted EPS ~$0.78 vs ~$0.82 expected.
At a Glance
A balance sheet — strong enough to weather a downturn
65/100 earnings predictability — reasonably predictable
26.1x trailing p/e — priced about right
0.6% dividend yield — cash in your pocket every quarter
6.5% return on capital — normal for a large med-tech
XVARY composite: 72/100 — average
What They Do
Alcon makes surgical gear, lenses, and eye-care products that help people see better.
Alcon is the world's largest eye-care company. Surgical is 56% of sales and Vision Care is 44%. The company says it has surpassed 175 million IOLs (artificial lenses) implanted globally, so your doctor already knows the name and leaving is painful.
How They Make Money
~$10.3B
FY2025 net sales · ~+5% reported YoY (company release)
Cataract surgery devices
$2.5B
+5.0%
Retinal surgery devices
$1.4B
+5.0%
Refractive surgery and IOLs
$1.9B
+5.0%
Contact lenses
$3.0B
+4.0%
Lens care and ocular health
$1.6B
+4.0%
The Products That Matter
Implanted cataract lenses
Intraocular Lenses (IOLs)
175M+ implanted globally
more than 175M implanted lenses is installed-base evidence, not marketing gloss. it helps keep Alcon in surgeon workflows and hospital purchasing lists.
surgical anchor
Daily wear vision correction
Contact Lenses
$3.0B · ~29% of revenue
this ~$3.0B business is repeat-purchase vision care that does not depend on a surgeon booking an operating room.
recurring demand
Surgical platform systems
Surgical portfolio
~$5.8B combined surgical lines · ~+5% growth
Cataract, retinal, and refractive/IOL rows in the table sum to the bulk of sales; each system placed can pull consumables for years.
pull-through bet
Key Numbers
~$10.3B
FY2025 net sales
This is the size of the business. Alcon is huge, but ~5% reported growth is still a steady large-cap medtech cadence.
26.1x
trailing p/e
Jargon → price divided by profit → you are paying 26.1 years of last year's earnings.
6.5%
capital return
Jargon → profit on invested money → so what: management turns $100 of capital into $6.50 of operating profit.
23.0%
operating margin
Operating margin → operating income as a share of sales → about 23¢ of operating profit per $1 of revenue before interest and taxes (not “after overhead” in the plain-English sense).
Financial Health
A
Strength
- balance sheet grade A — very strong financial position
- risk rank 2 — safer than 80% of stocks
- price stability 80 / 100
- long-term debt $4.2B (9% of capital)
- net profit margin 16.2% — keeps 16 cents of every dollar in revenue
- return on equity 8% — $0.08 profit for every $1 investors have put in
A with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total Return vs. Market
You invested $10000 in ALC 3 years ago → it's now worth $10890.
The index would have given you $14770.
source: institutional data · total return
What Just Happened
missed estimates
Q4 2025 net sales ~$2.7B (+9% reported / +7% c.c.); core diluted EPS ~$0.78 vs ~$0.82 expected.
GAAP diluted EPS was ~$0.44 in Q4—do not merge GAAP and core lanes. Core gross margin ~62.5% (down ~50 bps YoY per release, tariffs vs. price).
~$2.7B
Q4 net sales
~$0.78
core diluted EPS
~62.5%
core gross margin
EPS miss
Core EPS missed by ~$0.04 (~4.9%) vs the ~$0.82 consensus—pair the same non-GAAP definition the release uses.
-
Alcon reported q4 2025 net sales of ~$2.7b, up 9% reported and 7% in constant currency; fy2025 sales ~$10.3b, up 5% reported.
-
Q4 core diluted eps ~$0.78 vs ~$0.82 expected; gaap diluted eps ~$0.44.
-
Surgical segment sales rose 5%, reflecting strength in consumables and acceleration in equipment sales.
-
The recently launched unity vcs (vitreoretinal cataract system) has gained traction across several key markets, while the clareon panoptix pro lens continues to resonate well with cataract surgeons, following its may 2025 launch.
-
Meanwhile, the vision care segment also saw a 5% sales increase, aiding in driving third-quarter adjusted operating income of $523 million and adjusted share net of $0.79.archived q3 commentary—superseded by the feb 2026 q4/fy2025 release linked in snap-source.
source: Alcon Q4 & FY2025 release (Feb 2026)
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
This is not a balance-sheet scare story. the real risk is paying 26.1x earnings for a business that looks dependable until pricing, procedure volumes, or margins wobble.
Med
Premium cataract pricing gets squeezed
Hospitals and surgery centers do not mind premium products until budgets get tighter. If buyers push back on premium equipment or lenses, the exact part of the story investors pay up for starts looking less premium.
A 10% price cut across the $5.8B surgical base would threaten roughly $580M of annual revenue.
Med
Elective procedures slow down
Cataract demand is recurring over time, but not every procedure happens on schedule. If patients delay treatment, consumables and implants feel it almost immediately.
A 5% decline in procedure volumes could reduce surgical revenue by about $290M annually.
Med
Currency translation muddies the headline
Alcon is Swiss and reports in U.S. dollars. Local demand can look fine while reported sales look softer simply because exchange rates moved against them.
Recent results showed a 1% currency drag, which is roughly a $100M headwind against a ~$10.3B revenue base.
Med
The multiple stops being generous
At 26.1x earnings, the stock does not need a broken business to fall. It only needs the market to decide that a ~5% grower deserves a more ordinary rating.
That is the lesson from the last 3 years: the business stayed solid, and the stock still lagged the market by $3,880 on a $10,000 starting investment.
The premium here rests on consistency. If pricing, procedure volumes, or margins wobble, the stock stops looking high quality and starts looking expensive.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Earnings
Next earnings report
May 18, 2026 is the next clean check-in. You want to see whether the recent pattern of 5% divisional growth and unchanged guidance still holds.
Margin
23.0% operating margin
This is the number protecting the premium multiple. If costs rise faster than sales, the valuation argument gets thinner fast.
Products
Unity VCS and Clareon adoption
Management keeps highlighting these products because new equipment placements and premium lens uptake are the clearest path to better mix. You are watching for proof that the talk turns into sustained demand.
Flow
Institutional selling trend
Institutions were net sellers for three straight quarters. If that reverses while guidance stays firm, sentiment can improve without the business changing much.
Analyst Rankings
earnings predictability
65 / 100
This business is steadier than most, but not immune to surprises. In human-speak: analysts see a relatively dependable company, not a metronome.
risk rank
2
Risk rank 2 means safer than about 80% of stocks. You are taking execution and valuation risk here more than balance-sheet risk.
Source: institutional data
Institutional Activity
institutions have been net selling for 3 consecutive quarters — 272 buyers vs. 308 sellers in 3q2025. total institutional holdings: 0.2B shares. net selling for 3 quarters.
Source: institutional data
Price Targets
3-5 year target range
$68
$127
$81
Current price
$98
Target midpoint · +21% from current · 3-5yr high: $140 (+75% · 15% ann'l return)
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive